Health
Deactivating gene could boost immunotherapy for head and neck cancer – Drug Target Review
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers were able to significantly slow the growth and spread of tumours in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant. The study was conducted…
-
Noosa News10 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General8 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News9 hours agoLyka Doggie Date Night at Moonlight Cinema
-
Noosa News8 hours agoQueensland Drug and Alcohol Court provides sentencing options – Proctor